Lung Cancer Clinical Trial Landscape: 1844 Active Trials, 677 Sponsors

1844

Active Trials

1006

Actively Recruiting

241

Phase 3 Active

677

Distinct Sponsors

Early Phase 1: 15 Phase 1: 492 Phase 2: 694 Phase 3: 241 Phase 4: 13

The lung cancer trial landscape in 2026

Lung cancer splits into two clinically distinct histologies. Non-small cell lung cancer (NSCLC) accounts for the large majority of trials and is increasingly segmented by molecular driver — EGFR, KRAS G12C, HER2, ALK, ROS1, BRAF, and RET — each with its own targeted-therapy program. Small cell lung cancer (SCLC) is a separate, faster-growing histology with a distinct trial set. A useful lung-cancer competitive picture has to track both the histology split and the molecular-subtype races at once.

Active lung cancer trials by subtype

Molecular-driver subtypes are subsets of NSCLC and overlap each other, so the rows below do not sum to the total above — each links to a dedicated biomarker landscape. KRAS G12C spans lung, colorectal, and pancreatic cancer; its page covers all indications.

By histology

Subtype	Active	Recruiting	Phase 3
Non-Small Cell Lung Cancer (NSCLC)	823	442	143
Small Cell Lung Cancer (SCLC)	189	103	22

By molecular driver (within NSCLC)

Subtype	Active	Recruiting	Phase 3
EGFR-mutant	175	80	37
KRAS G12C	55	27	13
HER2-mutant	57	35	6
ALK-positive	32	14	4
ROS1 fusion	19	8	3
BRAF V600E	5	2	1
RET fusion	4	0	0

Track every new lung cancer trial automatically

ClinicalTrials.gov updates daily. Our pipeline monitors it for you and delivers a clean digest every morning.

Get Free Alerts — No Credit Card

Most active industry sponsors

Largest industry-sponsored lung cancer trial portfolios by active study count:

Sponsor	Active Trials
AstraZeneca	89
Pfizer	31
Merck (MSD)	29
Roche / Genentech	28
Novartis Pharmaceuticals	20

What we monitor

Our pipeline pulls from ClinicalTrials.gov every day. For a lung cancer watch profile, alerts can be configured for:

New study registrations and status changes (e.g. opened to recruiting, completed)
Protocol changes — enrollment, endpoints, phase, and completion-date movements
New sponsor entrants into a subtype
Phase filters (Phase 1 for novel mechanisms, Phase 3 for registration programs)
Sponsor-type filters (large pharma vs. emerging biotech vs. academic)

Ready to automate your lung cancer trial monitoring?

Free plan — no credit card required. Set up your profile in 2 minutes.

Start Free

Frequently asked questions

How many lung cancer clinical trials are actively recruiting?

1006 lung cancer trials are actively recruiting on ClinicalTrials.gov, out of 1844 active studies overall (all non-completed statuses), including 241 in Phase 3. Counts on this page regenerate from ClinicalTrials.gov on every update.

What is the difference between NSCLC and SCLC trials?

Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) are distinct histologies with separate standards of care and trial sets. NSCLC trials are further segmented by molecular driver (EGFR, KRAS G12C, ALK, ROS1, HER2, BRAF, RET); SCLC trials are tracked on their own dedicated page.

Can I track a single lung cancer subtype?

Yes. Each subtype in the table above has its own landscape page, and in the dashboard you can create a watchlist scoped to one driver (for example EGFR-mutant or KRAS G12C) and receive a separate daily digest for it.

Pricing

Free — $0 forever: 1 disease tracker, weekly digest, ClinicalTrials.gov monitoring. No credit card required.

Starter — $49/month: 5 disease/keyword profiles, daily digest, all phase and sponsor filters. Best for individual analysts.

Pro — $149/month: Unlimited profiles, daily digest, priority support. Best for BD and CI teams.

Last updated: 2026-06-14 · Data from ClinicalTrials.gov · View full pipeline →

Lung Cancer Clinical Trial Landscape